Gyre Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M | — |
| Cost of Revenue | — | $5.4M | $3.9M | $4.6M | $4.8M | — | — | — |
| Gross Profit | — | $111.2M | $101.9M | $108.8M | $97.5M | — | — | — |
| Gross Margin | — | 95.4% | 96.3% | 95.9% | 95.3% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $13.7M | $12.0M | $13.8M | — | $68.9M | $53.0M | $43.9M |
| SG&A Expense | — | $20.8M | $16.1M | $14.7M | $17.4M | $19.0M | $16.2M | $13.4M |
| Operating Income | — | $11.5M | $16.2M | $-67.2M | $9.2M | $-87.9M | $-57.4M | $-57.3M |
| Operating Margin | — | 9.9% | 15.3% | -59.3% | 9.0% | -1,197.8% | -273.9% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $14.4M | $23.2M | $-77.0M | $9.4M | $-87.9M | — | — |
| Income Tax Expense | — | $4.6M | $5.3M | $8.5M | $5.1M | — | — | — |
| Net Income | — | $9.9M | $17.9M | $-85.5M | $4.3M | $-87.9M | $-56.2M | $-55.2M |
| Net Margin | — | 8.5% | 16.9% | -75.3% | 4.2% | -1,198.3% | -268.5% | — |
| EPS (Basic) | — | $0.06 | $0.14 | $-1.41 | $0.04 | $-1.44 | $-1.47 | $-2.30 |
| EPS (Diluted) | — | $0.02 | $0.05 | $-1.41 | $0.03 | $-1.44 | $-1.47 | $-2.30 |
| Shares Outstanding (Basic) | 97.0M | 89.3M | 85.1M | 65.8M | 63.6M | 61.3M | 44.2M | 24.1M |
| Shares Outstanding (Diluted) | 97.0M | 103.2M | 102.3M | 65.8M | 75.7M | 61.3M | 44.2M | 24.1M |
| Dividends Per Share | — | — | — | — | $0.24 | — | — | — |